Jakafi and Hypovolaemia - a phase IV clinical study of FDA data

Summary:

Hypovolaemia is reported as a side effect among people who take Jakafi (ruxolitinib phosphate), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Aldactone, and have Essential thrombocythaemia.

The phase IV clinical study analyzes which people have Hypovolaemia when taking Jakafi. It is created by eHealthMe based on reports of 56,447 people who have side effects when taking Jakafi from the FDA, and is updated regularly.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

What is Hypovolaemia?

Hypovolaemia (a decreased volume of circulating blood in the body) is found to be associated with 899 drugs and 835 conditions by eHealthMe. Check the latest studies of Hypovolaemia.

On Jul, 07, 2026

56,447 people reported to have side effects when taking Jakafi.
Among them, 16 people (0.03%) have Hypovolaemia.

Among these 16 people:

How long have people been on Jakafi when they have Hypovolaemia? *

What is the gender of people who have Hypovolaemia when taking Jakafi? *

female: 28.57 %
male: 71.43 %

What is the age of people who have Hypovolaemia when taking Jakafi? *

What are other drugs people take besides Jakafi? *

Metoprolol Succinate: 4 people, 25.00%
Prasugrel Hydrochloride: 4 people, 25.00%
Allopurinol: 4 people, 25.00%
Aspirin: 4 people, 25.00%
Entresto: 4 people, 25.00%
Ferrlecit: 4 people, 25.00%
Furosemide: 4 people, 25.00%
Hydroxyurea: 4 people, 25.00%
Nitroglycerin: 4 people, 25.00%
Aldactone: 4 people, 25.00%

What are other side effects people have besides Hypovolaemia? *

Anaemia (lack of blood): 9 people, 56.25%
Hypotension (abnormally low blood pressure): 9 people, 56.25%
Acute Kidney Failure: 6 people, 37.50%
Weakness: 6 people, 37.50%
Haemoglobin Decreased: 5 people, 31.25%
Haematoma (collection of blood outside the blood vessels): 5 people, 31.25%
Fatigue (feeling of tiredness): 4 people, 25.00%
Kidney Stones: 4 people, 25.00%
Heart Rate Decreased: 4 people, 25.00%
Arrhythmias (irregular heartbeat): 4 people, 25.00%

What are the existing conditions these people have? *

Essential Thrombocythaemia (chronic blood cancer): 4 people, 25.00%
Urinary Tract Infection: 3 people, 18.75%
Pain: 3 people, 18.75%
Iron Binding Capacity Total Abnormal: 2 people, 12.50%
Sedation: 1 person, 6.25%
Nausea (feeling of having an urge to vomit): 1 person, 6.25%
Menstruation Irregular: 1 person, 6.25%
Inflammation: 1 person, 6.25%
High Blood Pressure: 1 person, 6.25%
Diarrhea: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and have Hypovolaemia?

- Check whether Hypovolaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Jakafi:

Jakafi (56,530 reports)

Hypovolaemia treatments and more:

Hypovolaemia (8,125 reports)

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypovolaemia:

Hypovolaemia (899 drugs)

Browse all the conditions that are associated with Hypovolaemia:

Hypovolaemia (835 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Jakafi) and Jakafi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.